Fattahi Masoom Seyed Hossein, Lari Shahrzad Mohammadzadeh, Fattahi Asieh Sadat, Ahmadnia Negin, Rajabi Mahla, NaderiKalat Maliheh
Thoracic Surgery, Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Pulmonologist, Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Clin Respir J. 2018 Mar;12(3):1076-1083. doi: 10.1111/crj.12630. Epub 2017 Apr 20.
Cystic echinococcosis (CE) is an endemic disease in Iran. This study has aimed to report the efficacy of Albendazole therapy in patients with CE.
Among 164 patients with echinococcosis who were referred to the surgery clinic, Ghaem hospital, Mashhad University of Medical Sciences between 2001 and 2013, two were diagnosed with alveolar echinococcosis (AE) and 162 with CE; 43 of whom underwent surgery. The rest 119 patients received medical therapy by Albendazole 15 mg/kg/day for three phases. Each phase included 6 weeks of Albendazole therapy followed by 2 weeks of no medication. The patients were classified according to radiologic evaluations into four groups: (1) cured, (2) improved, (3) unchanged, and (4) worsened or relapsed.
Patients who completed more phases had significantly greater chances of better response. Of the 56 patients who completed all three phases, 37 (66.1%) were cured, 15 (26.8%) improved, 4 (7.1%) remained unchanged, and none worsened or relapsed. [Odds ratio (OR):4.78, 95% confidence interval (CI): 2.95-7.74, P < .0001].
Albendazole can be beneficial for inoperable, multiple cysts, and multiple organs CE patients.
囊性棘球蚴病（CE）是伊朗的一种地方病。本研究旨在报告阿苯达唑治疗CE患者的疗效。
2001年至2013年期间，在马什哈德医科大学加姆医院外科门诊转诊的164例棘球蚴病患者中，2例被诊断为泡型棘球蚴病（AE），162例为CE；其中43例接受了手术治疗。其余119例患者接受阿苯达唑15mg/kg/天的药物治疗，分三个阶段进行。每个阶段包括6周的阿苯达唑治疗，随后2周不使用药物。根据放射学评估将患者分为四组：（1）治愈，（2）改善，（3）不变，（4）恶化或复发。
完成更多阶段治疗的患者有更好反应的机会显著更大。在完成所有三个阶段治疗的56例患者中，37例（66.1%）治愈，15例（26.8%）改善，4例（7.1%）不变，无恶化或复发者。[比值比（OR）：4.78，95%置信区间（CI）：2.95-7.74，P <.0001]。
阿苯达唑对无法手术的、多发性囊肿和多器官CE患者可能有益。
